Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Market Access Impact: Melanoma (EU5)

Product Code:
Publication Date:
February 2016

Compare 7 leading melanoma drugs. See why the 2nd-place brand is closing in on the top player

When oncologists can’t prescribe the drugs they want, brands lose market share—share that goes to the competition.

That’s a big concern for the leading brand in the European melanoma treatment market. Prescription limitations are helping its 2nd-place rival post impressive share gains.

The report compares 7 major melanoma treatments—Keytruda, Mekinist, Opdivo, Proleukin, Tafinlar, Yervoy, and Zelboraf.  You’ll get a detailed picture of what prevents doctors from prescribing your brand, who you’re losing market share to, and who you’re taking it from.

That’s information you can use to win back lost share and compete more effectively.

Not your market? Click here to see the US report


Request Sample Pages

Get Answers to Key Questions about Melanoma Drug Brands

  • Keytruda (pembrolizumab; Merck Sharp & Dohme): A top-3 brand in the US, where does Keytruda rank in the EU market?
  • Mekinist (trametinib; Novartis): How much of Mekinist’s share loss is driven by cost-related barriers?
  • Opdivo(nivolumab; Bristol-Myers Squibb): Does Opdivo gain more share because of other drugs’ limited availability or patient-type restrictions?
  • Proleukin (aldesleukin; Novartis): Proleukin sees a net market share gain against only one brand. Which one?
  • Tafinlar(dabrafenib; GlaxoSmithKline): Tafinlar gains almost 4 times as much share from one brand than from any others. Which one?
  • Yervoy(ipilimumab; Bristol-Myers Squibb): Which two barriers drive nearly two thirds of Yervoy’s impressive share gain?
  • Zelboraf (vemurafenib; Roche): Does Zelboraf lose more share to Yervoy or to various “other” brands?

Top Takeaways

  • Only three brands benefit from barriers: All 3 saw a net gain in market share, but one brand’s net gain is over 10 times that of the nearest competitor. 
  • Barriers have a moderate overall effect: In Europe, barriers affect close to 25% of prescriptions. Few oncologists experience more than 1 barrier with any given brand.
  • Market share impact greatest at the top and bottom: The first and last place brands see the biggest effect on share. Eliminating barriers would change rankings at both ends of the market.
  • Cost, labelling barriers have the greatest effect: barriers related to cost and patient type restrictions affect more prescriptions that any other barrier.
  • Competition is fierce at the top of the market: The two leading brands are neck and neck, but one of them looks to be on the rise.
  • Bottom of the market shows clear loser: The bottom-ranking brand is prescribed by almost 30% fewer oncologists than its closest competitor. Nearly 1/3 of oncologists won’t recommend it.
  • Huge barrier effect for “other” brands: Barriers give “other” brands one of the biggest net share gains. And if barriers didn’t exist, “other” brands would outrank 3 of the surveyed brands.
  • Important differences between Europe and US: In terms of both the brands most prescribed and the effect barriers have on prescribing. See the US report for details.

Exploring Market Access Issues

Market Access Impact: Melanoma explores key issues affecting melanoma drug manufacturers. You’ll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest effect?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don’t, but would consider it?
  • Why don’t doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 Medical Oncologists—30 from each EU5 country (France, Italy, Germany, Spain, UK)chosen from the largest community of validated physicians in the world.

All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with melanoma in total in the last month

We conducted the survey between January 4th and 19th, 2016.


At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.


All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved